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Development efforts in rural Africa over the last few decades 
have achieved improvements in living conditions and in health. 
It has been argued that when such changes occur, there will be a 
subsequent reduction in birth rates, and experience in other parts 
of the developing world has tended to bear out this prediction. 
However, birth rates in rural Africa remain high and the population 
continues to grow rapidly. The situation in Ethiopia provides 
an illustration; spiraling population growth and slow economic 
growth are widely considered to be the main factors that have 
fuelled this country’s repeated humanitarian crises. 
On the basis of current trends, it is predicted that Africa’s 
population will double in the next 50 years, but in many 
countries, the resources are currently not available to sustain 
such a level of growth, and increased human suffering may 
be the consequence. An important question, but one that is 
seldom discussed, is whether development programs in Africa 
fail to make sustainable improvements over the long term 
because they lead to unsustainable increases in population 
growth rate. This concern is addressed, however, in a paper by 
Gibson and Mace, who studied a rural development program 
that was intended to improve the lives of Ethiopian women. The 
researchers measured its impact on the health of women and 
children in eight villages included within the program, and also 
on the birth rate. 
The study involved a rural area where some villages had 
beneﬁ  ted from the provision of a tapped water supply. 
Previously, women had to walk long distances (up to 30 km) 
to fetch their families’ water in clay pots. The development 
program reduced the time they spent carrying water each day 
from about three hours to about 15 minutes. The researchers 
collected information over a four-year period, including for 
both villages where tapped water had been introduced and for 
others where it had not. In total, nearly 2,000 households were 
included. The nutritional status of the women and children (in 
terms of body mass index) was also measured. The researchers 
found that the availability of tapped water improved the survival 
of young children, although their nutritional status actually 
declined, and the birth rate increased. All this caused greater 
scarcity of resources within households.
The incremental effects of small changes to energy balance 
caused by development can increase strain on the household 
by increasing birth rates. This ﬁ  nding highlights the importance 
of continuing to improve access to contraception, especially in 
rural areas. 
Gibson MA, Mace R (2006) An energy-saving development initiative 
increases birth rate and childhood malnutrition in rural Ethiopia. 
DOI: 10.1371/journal.pmed.0030087
Birth Rate Increases following Improved Rural Water Supply
DOI: 10.1371/journal.pmed.0030133
The most common cause of nongenetic 
mental retardation in the Western world 
is fetal alcohol syndrome (FAS). About 
one in 1,000 United States children is born 
with FAS, which is caused by prenatal 
exposure to alcohol. Children with FAS 
typically have abnormal facial features 
and reduced growth. They also have 
central nervous system abnormalities that 
lead to impaired learning and memory 
skills, hyperactivity, and other behavioral 
problems. These neurological disabilities 
arise because ethanol disrupts the 
formation and survival of neurons in the 
developing brain, particularly in the last 
trimester of pregnancy and in the ﬁ  rst 
few years of postnatal life when brain 
development is particularly active.
There is no cure for FAS, but it is 100% 
preventable. Public health ofﬁ  cials 
recommend that women planning 
pregnancy and sexually active women 
who do not use effective birth control 
avoid alcohol—there is no safe dose of 
alcohol or safe time to drink it during 
pregnancy. Sadly, this advice is often 
ignored. In the US, one in 12 pregnant 
women admits to drinking alcohol, and 
one in 30 reports binge drinking (ﬁ  ve 
or more drinks at one time). Given such 
ﬁ  gures, ways to prevent or attenuate 
the effects of alcohol on the developing 
brain are badly needed. Alessandro 
Ieraci and Daniel Herrera now report that 
nicotinamide (the amide form of vitamin 
B3) can prevent some of the deleterious 
effects of ethanol on developing mice 
brains, and suggest that nicotinamide 
might be suitable as a preventative 
therapy for FAS.
Nicotinamide is the precursor of 
β-nicotinamide adenine dinucleotide, 
which enhances the action of many 
enzymes and is therefore essential 
for cellular function. Nicotinamide 
and other forms of vitamin B3 have 
been used for many years as dietary 
supplements to treat and prevent 
pellagra, a vitamin deﬁ  ciency disease. 
Large oral doses of nicotinamide have 
also been used over extended periods 
of time in clinical trials to treat type I 
diabetes and bullous pemphigoid (a 
chronic, autoimmune skin-blistering 
disease). In addition, recent animal 
data indicate that nicotinamide is also 
neuroprotective. In rat models of stroke, 
for example, it improves neurological 
outcomes by inhibiting the neuronal 
apoptosis caused by oxygen deprivation. 
In apoptosis (a highly organized form of 
cell death), mitochondrial breakdown 
releases the protein cytochrome-c, 
which activates enzymes known as 
initiator caspases. These activate effector 
caspases (including caspase-3), which 
digest other cellular substrates and kill 
the cell without releasing any potentially 
harmful molecules. Nicotinamide acts as 
a neuroprotectant in part by inhibiting 
cytochrome-c release and caspase-3 
activation.
Nicotinamide: A Way to Prevent Fetal Alcohol Syndrome?
DOI: 10.1371/journal.pmed.0030147
DOI: 10.1371/journal.pmed.0030147.g001
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Inﬂ  uenza is estimated to be responsible for a million deaths 
worldwide every year. In developed countries, epidemics of 
inﬂ  uenza have long been known to increase hospital admissions 
and mortality. This impact has been measured quantitatively in 
many studies dating back over a century. The statistical methods 
used in such research have involved both “comparative” and, 
more recently, “regressive” techniques. 
There are of course many difﬁ  culties in collecting and 
analyzing this kind of information in developing countries. In 
addition, the lack of clear seasonal patterns to epidemics in these 
regions prevents the use of regressive statistical methods. As a 
result, the impact of inﬂ  uenza on morbidity and hospitalization 
in the tropics and subtropics has been poorly quantiﬁ  ed. 
However, the Hong Kong Special Administrative Region, which 
has a subtropical climate and a modern health-care system, 
presents opportunities to conduct such research. Ninety-ﬁ  ve 
percent of the people admitted to hospital in Hong Kong go 
to public-sector hospitals, which have a central computerized 
system in which clinical records are kept on all patients.
In a new study, Peiris and colleagues present the results of a 
study in which they obtained information on patients admitted 
to hospitals in Hong Kong during the period 1996–2000. They 
developed an appropriate statistical technique that allowed 
them to capture inﬂ  uenza-associated mortality even in the 
absence of a predictable seasonal pattern of inﬂ  uenza, and 
also controlled for potential confounding factors as variations 
in temperature and humidity. The researchers found that 
during inﬂ  uenza outbreaks, hospital admissions increased, not 
just for respiratory diseases such as pneumonia but also for 
cardiovascular conditions and diabetes. The increases were most 
noticeable for older people. Overall, inﬂ  uenza was responsible for 
11.6% of admissions for respiratory disease, 1.5% of admissions 
for stroke, 1.8% of admissions for heart attacks, and 3.5% of 
admissions for diabetes. These ﬁ  gures are comparable with what 
has been found in developed countries outside the tropics. 
Inﬂ  uenza-Associated Hospitalization in a Subtropical City
DOI: 10.1371/journal.pmed.0030163
DOI: 10.1371/journal.pmed.0030163.g001
Weekly number of observed and ﬁ  tted hospitalizations, 
and percentage of specimens positive for inﬂ  uenza
As induction of apoptosis is one 
known mechanism by which ethanol 
harms neurons, Ieraci and Herrera asked 
whether nicotinamide could reduce the 
effects of ethanol in a mouse model of 
FAS. Subcutaneous injection of ethanol 
triggers widespread neurodegeneration 
in seven-day-old mice—whose brain 
development is comparable to that of 
human fetuses in the third trimester of 
pregnancy. The researchers report that 
an ethanol injection sufﬁ  cient to raise 
blood ethanol levels to those that a 
human fetus would be exposed to if its 
mother indulged in binge-like drinking 
activated caspase-3 and induced the 
release of cytochrome-c. They then show 
that nicotinamide injected up to eight 
hours after the ethanol reduced caspase-
3 activation and cytochrome-c release 
without altering blood or brain ethanol 
levels.
As the “normalizing” effects of 
nicotinamide were strongest when it 
was administered zero to two hours after 
alcohol exposure, Ieraci and Herrera 
next investigated whether nicotinamide 
given two hours after alcohol injection 
could prevent ethanol-induced neuronal 
death. To look for early signs of neuronal 
injury, they stained brain sections with 
Fluoro-Jade B soon after exposing the 
mice to ethanol. Most damage occurred 
in brain regions particularly sensitive 
to ethanol at this age—namely, the 
anterior cingulate cortex (which is 
involved in cognition), the hippocampus 
(a region needed for learning and 
memory), and the thalamus (which 
relays messages from the outside world 
to other brain regions); nicotinamide 
treatment reduced this damage. When 
the researchers stained brain sections 
for NeuN, a marker of mature neurons, 
several days after ethanol exposure, 
they found reduced numbers of neurons 
(compared with control brains) in similar 
brain regions, and, again, nicotinamide 
treatment reduced ethanol’s effects. 
Finally, the researchers used three 
standard behavioral assays to test 
whether the reduction in ethanol-
induced neuronal death produced by 
nicotinamide affected the behavior of 
adult mice. They report that nicotinamide 
reversed the increase in hyperactivity and 
the decrease in fear caused by ethanol 
exposure, and prevented the impairment 
in learning and memory induced by 
ethanol.
In mice, then, these results show that 
nicotinamide can reverse the molecular, 
cellular, and behavioral effects of ethanol 
exposure on developing brains. While the 
beneﬁ  cial effects observed were most 
pronounced when nicotinamide was 
given at the same time or shortly after 
alcohol exposure, the study suggests 
that there is a time window of a few 
hours during which treatment with 
nicotinamide might be effective. More 
studies are needed to determine exactly 
how nicotinamide protects neurons 
against alcohol-induced damage, 
but the data raise the possibility that 
nicotinamide treatment may provide a 
way to prevent some human cases of FAS.
Ieraci A, Herrera DG (2006) Nicotinamide 
protects against ethanol-induced apoptotic 
neurodegeneration in the developing mouse 
brain. DOI: 10.1371/journal.pmed.0030101
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The ﬁ  nding that the inﬂ  uenza burden faced by Hong Kong 
is in fact similar to that in the United States, for example, is 
important, as it has usually been assumed that inﬂ  uenza does 
not have a signiﬁ  cant impact on health outside the temperate 
regions. The results of this study suggest that inﬂ  uenza deserves 
to be given a higher priority than it is accorded at present 
in tropical and subtropical countries. The authors urge the 
introduction of vaccination programs for people at high risk, 
particularly the elderly.
Given the special circumstances of Hong Kong, some caution 
is of course required when extrapolating these ﬁ  ndings to other 
parts of the tropics and subtropics. A wealthy subtropical city 
with good infrastructure is different in very many respects from 
low-income nations in the tropics. Most tropical countries face 
a massive disease burden from other medical conditions and 
lack the level of resources for health care that are available in 
Hong Kong. Nevertheless, this is clearly an important study. Its 
implications are discussed further in the Perspective by Viboud, 
Alonso, and Simonsen (DOI: 10.1371/journal.pmed.0030089). 
They note, in particular, the ﬁ  nding that hospitalization of 
children with inﬂ  uenza is apparently greater in Hong Kong than 
in the US, and they suggest that childhood vaccination programs 
may need to be considered.
Wong CM, Yang L, Chan KP, Leung G, Chan KH, et al. (2006) 
Inﬂ  uenza-associated hospitalization in a subtropical city. DOI: 
10.1371/journal.pmed.0030121
In 1927, Cecil Alport described a family 
in which affected individuals developed 
progressive kidney failure, deafness, 
and sometimes eye problems. Alport 
syndrome, although it affects only one 
in 50,000 live births in the United States, 
is the second most commonly inherited 
reason for kidney failure. It is caused by 
mutations in the genes that encode type 
IV collagen, a structural component of 
the thin, sheet-like basement membrane 
that covers the glomeruli, the kidney’s 
ﬁ  ltration units. The glomerular basement 
membrane (GBM) normally ﬁ  lters ﬂ  uid 
and small molecules (but not proteins 
or red blood cells) from the capillaries 
in the glomeruli into the urine, but in 
Alport syndrome, the collagen scaffold of 
the GBM is defective and, over time, the 
GBM splits and thins. The ﬁ  rst symptom 
of Alport syndrome is blood in the urine 
(hematuria), followed by proteinuria 
and progressive renal failure as scar 
tissue (ﬁ  brotic tissue) forms around the 
glomeruli. The syndrome has no speciﬁ  c 
treatment, but kidney transplantation is 
usually successful in patients with end-
stage kidney failure.
There are six isoforms of type IV 
collagen—α1(IV) through α6(IV). In 
immature kidneys, the GBM contains 
α1(IV) and α2(IV), but these are replaced 
by α3(IV), α4(IV), and α5(IV) as the 
kidneys mature. The gene encoding 
α5(IV) is mutated in patients with X-
linked Alport syndrome (85% of cases); 
mutations in the genes encoding 
α3(IV) or α4(IV) cause other forms of 
the syndrome. In all cases, the normal 
switch in collagen isoforms does not 
occur as the kidneys mature. Raghu 
Kalluri and colleagues have been 
investigating whether this failure to 
switch might make the GBM more 
susceptible to proteolytic degradation 
by matrix metalloproteinases (MMPs). 
They now report that MMPs have a 
dual role during disease progression in 
a mouse model of Alport disease, and 
suggest that MMP inhibition might be 
therapeutic during the early stages of 
the human disorder.
The mouse model used by Raghu 
Kalluri, Michael Zeisberg, and colleagues 
to test their ideas about the pathogenesis 
of Alport syndrome is the α3(IV)−/− 
mouse, which lacks functional α3(IV) 
collagen. These mice are born normal, 
but by four to ﬁ  ve weeks old, their GBMs 
begin to disintegrate and they develop 
proteinuria. By eight weeks old, ﬁ  brotic 
tissue has formed in the tubulointerstitial 
compartment of their kidneys, and the 
mice die by 14 weeks old from kidney 
failure. The researchers ﬁ  rst examined the 
localization of MMP-2, MMP-3, and MMP-
9 (all of which degrade GBM) in α3(IV)−/− 
mice. Wild-type mice expressed low 
levels of these MMPs in their kidneys, but 
α3(IV)−/− mice expressed increased levels 
of MMP-2 and MMP-3 in their glomeruli 
at four weeks old, and as their disease 
progressed, expression of all three MMPs 
spread to the renal tubulointerstitial 
compartment. Renal expression of these 
MMPs was also increased in patients 
with X-linked Alport syndrome and end-
stage renal failure when compared with 
normal kidneys. Furthermore, GBM from 
humans with Alport syndrome and from 
α3(IV)−/− mice was more susceptible to 
MMP degradation than that from normal 
humans or mice.
These results support the idea that 
increased proteolytic degradation of 
a defective GBM may be responsible 
for Alport syndrome, but renal disease 
still occurs in α3(IV)−/− mice when 
MMP-9 is missing. Could other MMPs 
compensate for the loss of MMP-9? When 
the researchers examined renal tissue 
from α3(IV)−/− mice deﬁ  cient for MMP-2 
and/or MMP-9, they did indeed discover 
compensatory upregulation of other 
MMPs. So the researchers then looked 
to see whether pharmacological agents 
that inhibit multiple GBM-degrading 
MMPs could alter disease progression in 
α3(IV)−/− mice. The researchers report that 
giving such drugs to four-week-old mice 
(before proteinuria developed) delayed 
disease progression and increased their 
survival by ﬁ  ve weeks. However, giving 
the same drugs to eight-week-old mice 
(in which there was tubulointerstitial 
ﬁ  brosis) shortened their lives by two to 
three weeks.
Based on these animal experiments, 
the researchers suggest that in patients 
with Alport syndrome, the GBM (unlike 
GBM in healthy individuals) is susceptible 
to degradation by the low levels of 
MMP normally present in the kidney. 
Alport Syndrome: From Pathogenesis to a Potential Therapy
DOI: 10.1371/journal.pmed.0030154
DOI: 10.1371/journal.pmed.0030154.g001
Transmission electron microscopy of a 
kidney from an α3(IV)–/– mouse. Without 
treatment, glomerular basement 
membrane lesions and podocyte 
effacement cause severe proteinuria in 
these mice.
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For many people in the developed 
world, a diagnosis of HIV/AIDS is 
no longer a death sentence. Since 
the introduction in the 1990s of 
effective antiretroviral therapy (ART)—
combinations of three or four drugs that 
interfere with different stages of the 
HIV life cycle—HIV/AIDS mortality rates 
have dropped by 50%–70% in afﬂ  uent 
countries. By contrast, in developing 
countries, at least 6 million people need 
immediate access to ART but fewer than 
10% of them get it. In 2005, 3 million 
people in poor countries died from HIV/
AIDS. To improve this situation, the World 
Health Organization (WHO), the Joint 
United Nations Programme on HIV/AIDS 
(UNAIDS), and other international bodies 
are working toward providing universal 
access to ART for all those who need it 
by 2010. In addition to reducing AIDS 
morbidity and mortality, the hope is that 
this strategy will also reduce HIV/AIDS 
prevalence, because sexual transmission 
of HIV is more likely if the partner who is 
HIV-positive has a high viral load. 
Many challenges need to be overcome 
to achieve universal access to ART, 
not least of which is determining 
how to maximize the beneﬁ  ts of ART 
to patients and their communities 
in resource-poor settings. Regional 
differences in health-care facilities, 
local changes in sexual behavior in 
response to treatment, and many other 
factors can alter how ART affects both 
HIV transmission rates and HIV/AIDS 
mortality. Ideally, the best strategy 
for each setting would be determined 
through large-scale randomized trials 
of different approaches—for example, 
the time at which treatment is initiated 
relative to the time of infection—with 
HIV prevalence and HIV/AIDS–related 
mortality as primary endpoints. However, 
such trials are lengthy and costly, so 
researchers and policy makers are also 
using mathematical models to explore 
the impacts of different treatment and 
monitoring strategies. Rebecca Baggaley 
and colleagues now describe a new 
approach to modeling the impact of 
ART in resource-poor settings. Their 
model predicts that HIV epidemics in 
sub-Saharan Africa will not be controlled 
through ART alone, even if universal 
access is achieved. Additional prevention 
methods such as counseling patients 
and their communities about safe sex 
are essential. Without them, their results 
suggest, access to ART is likely to increase 
HIV/AIDS prevalence. 
The researchers’ deterministic model 
of HIV transmission incorporates ART 
and stratiﬁ  es infection progression into 
four different stages (primary infection, 
incubation, pre-AIDS, and AIDS), each 
of which is associated with a different 
degree of infectiousness. In effect, the 
model is a complex ﬂ  owchart through 
which patients move inexorably as 
they become infected and receive 
treatment—which can fail (virologic 
failure) or succeed (long-term viral 
suppression)—or from which they 
can withdraw. Sexual behavior and 
changes in sexual behavior in response 
to HIV/AIDS and ART is also plugged 
into the model—people treated with 
antiretrovirals often become more 
sexually active as they begin to feel 
better. Effective counseling, on the other 
hand, can increase safe-sex practices. 
To turn this ﬂ  owchart into predictions 
of how HIV epidemics in sub-Saharan 
Africa might develop over time given 
different ART strategies and, for example, 
the availability of diagnostic laboratories 
Antiretroviral Use in Resource-Poor Settings: Modeling Its Impact
DOI: 10.1371/journal.pmed.0030179 
Partial disruption of the GBM attracts 
inﬁ  ltrating monocytes, which increase 
local MMP concentrations and accelerate 
GBM destruction. MMP inhibitors during 
this phase of the syndrome should be 
protective, suggest the researchers, 
but once the damage is sufﬁ  cient to 
stimulate renal ﬁ  brosis, the same drugs 
will accelerate disease progression 
by inhibiting the MMPs that normally 
help to degrade ﬁ  brotic tissue. MMP 
inhibitors are already being developed 
for other indications and would be 
worth investigating as preventive drugs 
in Alport syndrome. But, warn Kalluri 
and colleagues, these drugs would be a 
double-edged sword, and could only be 
used in patients with identiﬁ  ed genetic 
defects and only before the onset of 
proteinuria. 
Zeisberg M, Khurana M, Rao VH, Cosgrove 
D, Rougier JP, et al. (2006) Stage-speciﬁ  c 
action of matrix metalloproteinases 
inﬂ  uences progressive hereditary 
kidney disease. DOI: 10.1371/journal.
pmed.0030100
to monitor the immune status and 
viral load of individuals with HIV, the 
researchers used published estimates of 
relevant parameters such as the fraction 
of patients that drop out at each stage 
of treatment and the transmission 
probability per sexual partnership for 
patients in whom ART failed.
Baggaley and her colleagues make 
several predictions. They suggest, for 
example, that unlimited ART provision 
initiated once patients have developed 
AIDS will increase the prevalence of 
infection (because the patients live 
longer and become sexually active 
again), a worrying result given that one 
aim of the universal access initiative is to 
reduce HIV infection rates. Furthermore, 
although different coverage levels 
in this scenario will not affect the 
years of life gained per person-year 
of treatment, increased coverage will 
increase the emergence and spread of 
drug resistance. If pre-AIDS patients are 
treated as well, the researchers predict 
that additional infections will be averted 
per person-year of treatment, but the 
effect will be small and highly dependent 
on how pre-AIDS patients change their 
sexual behavior in response to ART. 
As with all modeling exercises, this 
new model includes many assumptions 
that may limit its applicability in the “real 
world.” For example, it includes only 
ﬁ  rst-line triple-therapy ART and does 
not allow for second-line therapy if one 
drug regimen fails; it does not consider 
the sexual behavior of people who don’t 
know they are infected with HIV; and 
it does not allow for a reduction in the 
quality of ART programs as coverage 
increases, a likely problem in countries 
with limited resources. Nevertheless, the 
model’s predictions sound a warning: ART 
is not likely to function as a direct method 
for transmission prevention even when 
coverage is high. Counseling of patients 
and their communities to promote safe 
sexual practices must accompany ART 
provision. Difﬁ  cult decisions regarding 
the allocation of ﬁ  nite resources will 
have to be made as ART is rolled out 
in resource-poor countries, conclude 
the researchers, decisions that can best 
be made by combining mathematical 
modeling with data from early programs 
as they become available. 
Baggaley RF, Garnett GP, Ferguson 
NM (2006) Modelling the impact of 
antiretroviral use in resource-poor settings. 
DOI: 10.1371/journal.pmed.0030124
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Mosquito-borne ﬂ  aviviruses such as 
Japanese encephalitis virus (JEV) and 
West Nile virus (WNV) are two of the most 
important examples of emerging and 
resurging pathogens. Currently, there 
are no effective drugs available to treat 
these infections. Moreover, infections 
by diverse neurotropic ﬂ  aviviruses are 
clinically indistinguishable, which makes 
it important to develop broad-based 
therapies effective against multiple 
ﬂ  aviviruses.
In a new study, Priti Kumar and 
colleagues examined whether RNA 
interference (RNAi)–based intervention 
could suppress lethal JEV and WNV 
encephalitis in mice. RNAi is a process 
in which short double-stranded RNA 
(dsRNA) called short interfering RNA 
(siRNA) inhibits gene expression in 
a sequence-speciﬁ  c manner. This 
process was ﬁ  rst discovered in plant 
cells, and there is still speculation 
concerning its implications for human 
physiology. However, RNAi has 
emerged as a powerful technique for 
posttranscriptional gene silencing, useful 
in both research and, potentially, the 
development of new therapies.
Studies of RNAi in plants, invertebrates, 
and, more recently, mammalian 
cells have all hinted at the potential 
of this method. RNAi-mediated 
posttranscriptional gene silencing 
RNA Interference to Suppress Flaviviral Encephalitis
DOI: 10.1371/journal.pmed.0030139
DOI: 10.1371/journal.pmed.0030139.g001
Section from JEV-infected mouse brain 
obtained after treatment with control or 
JEV-speciﬁ  c siRNA
By the year 2020, global deaths from noncommunicable 
diseases are expected to increase by 77%. The projected rise is 
mainly due to the aging of the population and to an increase in 
the numbers of people exposed to tobacco. While antismoking 
campaigns have met with some success in developed countries, 
the tobacco epidemic is growing in many of the world’s 
developing and most populous countries. Tobacco (a major risk 
factor not only for lung cancer but also for chronic obstructive 
pulmonary diseases such as emphysema) is expected to kill more 
people than any single disease, surpassing even the HIV epidemic.
The link between tobacco smoke and lung cancer is striking, 
but not all smokers get lung cancer, and not all lung cancer 
patients have a history of ﬁ  rst- or second-hand exposure to 
tobacco smoke. Tobacco smoke contains carcinogens such as 
benzopyrene, which can cause mutations in the DNA of cells 
it comes in contact with, such as lung epithelial cells. Cytosolic 
enzymes such as those of the glutathione S-transferase 
(GST) family are part of the human body’s armor against 
environmental carcinogens; they catalyze the detoxiﬁ  cation 
of reactive electrophilic compounds like benzopyrene. Like 
all human genes, those encoding members of the GST family 
exist in multiple variant forms or alleles. Some of these alleles 
encode less-active or completely inactive versions of the 
detoxifying enzymes, and, therefore, might convey increased 
risk for the development of cancers with strong environmental 
determinants, and lung cancer in particular. 
Although more than 100 studies have tested the hypotheses 
that particular GST alleles either predispose to or protect 
against lung cancer, the results have been inconsistent, with 
some studies reporting strong associations and others failing 
to replicate these ﬁ  ndings. Individual association studies are 
notoriously prone to error, and attempts to combine results from 
several studies have been complicated by the fact that allele 
frequencies for many of the alleles differ between populations, 
by differences in smoking habits, and by differences in criteria 
for the selection of suitable control groups. 
To summarize the current evidence comprehensively and 
attempt to resolve the controversy, Zheng Ye and colleagues 
undertook a large meta-analysis of 130 published studies that 
had examined associations between one or several of ﬁ  ve GST 
alleles and lung cancer. The ﬁ  ve alleles included the GSTM1 
and GSTT1 null alleles, two missense alleles in GSTP1, and one 
intron polymorphism in GSTM3. (The null alleles abolish enzyme 
activity; the three other alleles encode enzymes with reduced 
activity.) A total number of 23,452 lung cancer cases and 30,397 
controls were included in the meta-analysis. Ye and colleagues 
corresponded with the individual research groups to obtain the 
data in tabular form and—for a few of the studies—additional 
data that were not included in the original publications. 
When taking all the existing evidence together, neither the 
I105V or A114V polymorphisms in GSTP1 nor the GSTM3 intron 
6 polymorphism were found to be associated with increased 
risk of lung cancer. The two “null” polymorphisms in GSTM1 
and GSTT1 showed a weak association. However, as Ye and 
colleagues discuss, it is possible that the weak overall link results 
from bias toward publication of positive results, especially 
for smaller studies. This is consistent with the result that the 
researchers obtained when they restricted their analysis to larger 
studies: comparing only cases and controls from studies that had 
at least 500 participants resulted in no signiﬁ  cant associations 
between any of the alleles and lung cancer. 
While meta-analyses such as this one have their own 
limitations, the results reported here make it unlikely that any of 
the ﬁ  ve polymorphisms convey a substantially enhanced lung 
cancer risk in the general population. This does not exclude the 
possibility that other alleles in the four genes examined here, 
alleles in other GST genes, or combinations of GST alleles do 
exert substantial inﬂ  uences on an individual’s lung cancer risk. 
As the authors conclude, the chances for discovering such links 
in future studies are likely much higher if such studies are large 
and carefully designed. 
Ye Z, Song H, Higgins JPT, Pharoah P, Danesh J (2006) Five 
glutathione S-transferase gene variants in 23,452 cases of lung cancer 
and 30,397 controls: Meta-analysis of 130 studies. DOI: 10.1371/
journal.pmed.0030091
Do Variants in the GST Detoxiﬁ  cation Genes Affect the Risk of Lung Cancer?
DOI: 10.1371/journal.pmed.0030174
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One out of every two women and one in eight men over 
50 will have an osteoporosis-related fracture in their lifetime. 
Osteoporosis is characterized by low bone mass and structural 
deterioration of bone tissue, and often progresses without overt 
symptoms or pain until a bone breaks. Fractures occur typically 
in the hip, spine, and wrist. Currently, there is no accurate 
measure of overall bone strength. Bone mineral density (BMD) 
is frequently used as a proxy measure, but it can explain only a 
modest proportion of fracture risk. 
Bone resorption and bone formation take place throughout 
life. Formation outpaces resorption until peak bone mass 
(maximum bone density and strength) is reached around age 
30. From then on, bone resorption slowly begins to exceed bone 
formation, and the balance is further shifted toward resorption 
in women after menopause. Osteoporosis develops when bone 
resorption occurs too quickly or replacement too slowly—which 
happens in most individuals at a certain age and often earlier in 
individuals who did not reach optimal bone mass during their 
bone building years.
Both bone formation and resorption are under the control of 
genetic and environmental factors. Osteoporosis is a “complex 
disease,” with variations in a number of different genes and in 
several environmental factors (such as calcium intake or alcohol 
consumption) thought to affect an individual’s risk. A number 
of candidate genes have been identiﬁ  ed, some of them through 
studies of rare genetic diseases affecting bone health, others 
through animal studies. They include genes for calciotropic 
hormones and their receptors, as well as bone matrix proteins. 
One of them, COLIA1, encodes collagen 1 alpha 1, a major 
component of bone and cartilage. Mutations in its coding 
region cause osteogenesis imperfecta, a rare developmental 
bone disorder characterized by brittle bones, frequent fractures, 
and short stature. Apart from these rare mutations, COLIA1 
has a number of polymorphic sites outside the coding region, 
and scientists have examined associations between many of 
these alleles and osteoporosis. The one that has been studied 
most intensely is a single-nucleotide polymorphism within the 
promoter region at a binding site for the Sp1 transcription factor. 
The more common allele has a guanine nucleotide (G) at the 
variable position; the rarer one, a thymine (T). In vitro studies 
suggest that the T allele is associated with less transcript and 
protein produced. 
Several previous studies had examined a possible association 
between the T allele and low bone mineral density and 
fractures, and a number of them had found such a link, as 
had three separate meta-analyses. As a consequence, some 
researchers have suggested that genetic testing at the 
population level for this polymorphism would be beneﬁ  cial. 
Individuals who carry the T allele could be advised to get 
enough calcium and do weight-bearing exercises, ideally 
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appears to have evolved to protect 
against invading genetic elements 
such as transposons and viruses. In 
mammals, although exposure to dsRNAs 
greater than 30 base pairs in length 
induces an antiviral interferon response 
that represses mRNA translation 
globally, shorter siRNA introduced into 
mammalian cells leads to speciﬁ  c mRNA 
degradation without activating the 
interferon response. 
Previous work has shown that infection 
by respiratory syncytial virus (RSV) 
and parainﬂ  uenza virus (PIV) could be 
speciﬁ  cally prevented and inhibited 
by siRNAs. In an RSV mouse model, 
researchers used siRNA to target the 
P protein, a key subunit of the viral 
RNA–dependent RNA polymerase, and 
found that it strongly inhibited RSV 
gene expression and RSV growth in 
culture. They also showed that single and 
concurrent infections in mice could be 
prevented and treated by speciﬁ  c siRNA 
applied exclusively intranasally. Their 
ﬁ  ndings suggested that inhaled siRNA 
could be a promising strategy for anti-
RSV and anti-PIV therapy in humans.
Studies have also demonstrated that 
siRNAs expressed by a lentivirus vector 
could prevent and treat inﬂ  uenza A 
virus (IAV) pneumonia in mice. When 
siRNAs speciﬁ  c for conserved regions 
of the IAV genes (nucleoprotein, acid 
polymerase, and basic polymerase 1) 
were administered prior or subsequent 
to the virus challenge, there were 
reductions in lung virus titers, lethality, 
or both. Based on these results, in a 
recent review of siRNAs for treating 
inﬂ  uenza, Jack Bennink and Tara Palmore 
have suggested that siRNAs could lead 
to a therapeutic solution against the 
variability of the IAV hemagglutinin. 
Kumar and colleagues from Harvard 
University describe promising results 
for the therapeutic potential of RNAi in 
treating viral encephalitis, both virus-
speciﬁ  c and across species. They induced 
RNAi in mice, with either a lentivirally 
expressed short hairpin RNA or a synthetic 
siRNA. By targeting a species-speciﬁ  c 
sequence in cd loop coding region in 
domain II of the viral envelope protein 
for JEV or WNV, the team achieved 
speciﬁ  c protection in mice against the 
corresponding virus. And in addition, by 
targeting a sequence within the cd loop 
that is conserved across both viral species, 
they were able to protect mice against 
encephalitis induced by both viruses.
These results suggested that a single 
treatment with siRNA may be sufﬁ  cient 
for protection against fatal encephalitis, 
which is encouraging from a therapeutic 
angle. In one set of experiments, they 
showed that single administration of 
siRNA could provide more than 60% 
protection even when administered 18 
hours after infection. This time frame 
is relevant because the burst phase for 
JEV and WNV replication is around 18 
hours—when many virus progeny are 
released.
However, although a single lipid–
based siRNA delivery in the brain 
parenchyma caused some degree of 
lateral spread and offered protection 
even in an established infection, this 
approach is unlikely to work when the 
infection has spread across the brain. This 
observation is important for potential 
clinical applications since usually 
treatments are not given until after the 
appearance of clinical symptoms.
To address this limitation, the authors 
suggest, further studies will have to focus 
on developing improved methods for 
siRNA delivery to brain cells. And much 
work will need to be done to establish 
the safety of this approach in humans. 
But RNAi technology may be shifting 
from a laboratory tool to a realistic 
treatment for viral infection.
Kumar P, Lee SK, Shankar P, Manjunath 
N (2006) A single siRNA suppresses fatal 
encephalitis induced by two different 
ﬂ  aviviruses. DOI: 10.1371/journal.
pmed.0030096
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already during the bone acquisition phase in adolescence. 
Others have warned that the evidence that links the T allele to 
a higher risk for osteoporosis is not strong enough to support 
such action. They have pointed out some of the notorious 
problems with association studies in general and retrospective 
meta-analyses based on published studies. 
The Genetic Markers for Osteoporosis (GENOMOS) project 
is a European Union–funded European collaborative research 
initiative between universities in the Netherlands, United 
Kingdom, Italy, Spain, Greece, Poland, and Denmark. The 
project, which began in 2003, currently involves around 
24,000 individuals and seeks to identify genetic risk factors for 
osteoporosis by prospective meta-analysis. Participants have 
been recruited from a total of 18 European countries (most of 
them reside in the UK, the Netherlands, Spain, Italy, Denmark, 
and Poland). Data on previous and new fractures are collected, 
together with bone densitometry measurements, information on 
risk factors, and DNA analysis from blood samples. 
The GENOMOS investigators, led by John Ioannidis, report 
now on their examination of an association between the Sp1 
polymorphism in COLIA1, BMD, and fracture risk. Based on data 
from over 20,000 participants, they found a modest association 
between homozygosity for the T allele and lower bone 
mineral density at the femoral neck and the lumbar spine. The 
researchers also found a weak association between the T allele 
and vertebral fractures in women. However, T allele carriers did 
not have an overall increased risk of fractures. 
The effects seen in this large study—GENOMOS participants 
reported more than ﬁ  ve times the number of fractures than 
participants in all previous studies combined—were more 
moderate than those reported in most of the earlier studies. 
The Sp1 polymorphism in COLIA1 explained only a small part of 
the differences in BMD and fracture risk among the GENOMOS 
participants. There was no association between the T allele and 
BMD in heterozygous carriers (and only approximately 4% of the 
participants were homozygous for the T allele). Regarding the 
fracture association, the researchers estimate that the presence 
of the T allele would explain at most 10% of the risk of vertebral 
fractures for women. 
The authors conclude that “large-scale studies are needed 
to quantify the true effect size of genetic polymorphisms that 
have been implicated in the pathogenesis of complex genetic 
disorders.” Their ﬁ  ndings also argue against widespread genetic 
testing for this particular polymorphism alone. Researchers 
need to look at other genes (and possibly other variants in the 
COLIA1 gene) and validate any ﬁ  ndings in large studies like this 
one before they can predict a substantial fraction of a random 
individual’s genetic risk for osteoporosis. 
Ralston SH, Uitterlinden AG, Brandi ML, Balcells S, Langdahl BL, 
et al. (2006) Large-scale evidence for the effect of the COLIA1 Sp1 
polymorphism on osteoporosis outcomes: The GENOMOS study. 
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